Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.

D. M. Dawson, J. L. Carter, D. A. Hafler, H. L. Weiner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our work with multiple sclerosis has demonstrated a favorable effect on the course of chronic progressive multiple sclerosis in two-thirds of patients treated with cyclophosphamide/ACTH. However, alternative methods of therapy, or repeated treatments with cyclophosphamide and ACTH are required for longer term control of the illness. We are attempting to assess the efficacy of outpatient maintenance cyclophosphamide, but do not as yet have any data to support the use of this form of treatment. Cyclophosphamide and ACTH can be given to multiple sclerosis patients without significant serious toxicity. Monoclonal antibody therapy of multiple sclerosis is in its beginning stages. The treatment appears to be safe and has produced some interesting data indicating that rapid entry of some labeled lymphocytes into the nervous system can be measured by this technique. Since these are phase one pilot trials designed to assess immune parameters and only small numbers of patients have been treated, no clinical results have been obtained. No adverse effects of monoclonal antibody therapy were observed.

Original languageEnglish (US)
Pages (from-to)88-91
Number of pages4
JournalRivista di Neurologia
Volume57
Issue number2
StatePublished - Mar 1987
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Cyclophosphamide
Immunosuppression
Multiple Sclerosis
Monoclonal Antibodies
Adrenocorticotropic Hormone
Chronic Progressive Multiple Sclerosis
Therapeutics
Complementary Therapies
Nervous System
Outpatients
Maintenance
Lymphocytes

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. / Dawson, D. M.; Carter, J. L.; Hafler, D. A.; Weiner, H. L.

In: Rivista di Neurologia, Vol. 57, No. 2, 03.1987, p. 88-91.

Research output: Contribution to journalArticle

Dawson, D. M. ; Carter, J. L. ; Hafler, D. A. ; Weiner, H. L. / Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. In: Rivista di Neurologia. 1987 ; Vol. 57, No. 2. pp. 88-91.
@article{b18ca21a9f164f56a0382add450ef348,
title = "Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.",
abstract = "Our work with multiple sclerosis has demonstrated a favorable effect on the course of chronic progressive multiple sclerosis in two-thirds of patients treated with cyclophosphamide/ACTH. However, alternative methods of therapy, or repeated treatments with cyclophosphamide and ACTH are required for longer term control of the illness. We are attempting to assess the efficacy of outpatient maintenance cyclophosphamide, but do not as yet have any data to support the use of this form of treatment. Cyclophosphamide and ACTH can be given to multiple sclerosis patients without significant serious toxicity. Monoclonal antibody therapy of multiple sclerosis is in its beginning stages. The treatment appears to be safe and has produced some interesting data indicating that rapid entry of some labeled lymphocytes into the nervous system can be measured by this technique. Since these are phase one pilot trials designed to assess immune parameters and only small numbers of patients have been treated, no clinical results have been obtained. No adverse effects of monoclonal antibody therapy were observed.",
author = "Dawson, {D. M.} and Carter, {J. L.} and Hafler, {D. A.} and Weiner, {H. L.}",
year = "1987",
month = "3",
language = "English (US)",
volume = "57",
pages = "88--91",
journal = "Rivista di Neurologia",
issn = "0035-6344",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.

AU - Dawson, D. M.

AU - Carter, J. L.

AU - Hafler, D. A.

AU - Weiner, H. L.

PY - 1987/3

Y1 - 1987/3

N2 - Our work with multiple sclerosis has demonstrated a favorable effect on the course of chronic progressive multiple sclerosis in two-thirds of patients treated with cyclophosphamide/ACTH. However, alternative methods of therapy, or repeated treatments with cyclophosphamide and ACTH are required for longer term control of the illness. We are attempting to assess the efficacy of outpatient maintenance cyclophosphamide, but do not as yet have any data to support the use of this form of treatment. Cyclophosphamide and ACTH can be given to multiple sclerosis patients without significant serious toxicity. Monoclonal antibody therapy of multiple sclerosis is in its beginning stages. The treatment appears to be safe and has produced some interesting data indicating that rapid entry of some labeled lymphocytes into the nervous system can be measured by this technique. Since these are phase one pilot trials designed to assess immune parameters and only small numbers of patients have been treated, no clinical results have been obtained. No adverse effects of monoclonal antibody therapy were observed.

AB - Our work with multiple sclerosis has demonstrated a favorable effect on the course of chronic progressive multiple sclerosis in two-thirds of patients treated with cyclophosphamide/ACTH. However, alternative methods of therapy, or repeated treatments with cyclophosphamide and ACTH are required for longer term control of the illness. We are attempting to assess the efficacy of outpatient maintenance cyclophosphamide, but do not as yet have any data to support the use of this form of treatment. Cyclophosphamide and ACTH can be given to multiple sclerosis patients without significant serious toxicity. Monoclonal antibody therapy of multiple sclerosis is in its beginning stages. The treatment appears to be safe and has produced some interesting data indicating that rapid entry of some labeled lymphocytes into the nervous system can be measured by this technique. Since these are phase one pilot trials designed to assess immune parameters and only small numbers of patients have been treated, no clinical results have been obtained. No adverse effects of monoclonal antibody therapy were observed.

UR - http://www.scopus.com/inward/record.url?scp=0023300907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023300907&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 88

EP - 91

JO - Rivista di Neurologia

JF - Rivista di Neurologia

SN - 0035-6344

IS - 2

ER -